HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer
Crossref DOI link: https://doi.org/10.1186/s12885-016-2385-z
Published Online: 2016-06-03
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Miller, Kathy
Cortes, Javier
Hurvitz, Sara A.
Krop, Ian E.
Tripathy, Debu
Verma, Sunil
Riahi, Kaveh
Reynolds, Joseph G.
Wickham, Thomas J.
Molnar, Istvan
Yardley, Denise A.
Funding for this research was provided by:
Merrimack Pharmaceuticals